Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Cancer Pain 1Breast Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Antibodies × Clear all
NCT03280563 2025-11-10

MORPHEUS HR+BC

Hoffmann-La Roche

Phase 1/2 Completed
144 enrolled 25 charts
Breast

Breast Neoplasms

NCT07008703 2025-06-06

Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 1/2 Recruiting
132 enrolled

Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡